"Surgical Apgar Score" predicts postoperative complications after cytoreduction for advanced ovarian cancer.
Gynecol. Oncol., Mar;116(3):370-3 (2010)
A microRNA expression signature for cervical cancer prognosis.
Cancer Res., Feb;70(4):1441-8 (2010)
Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.
J. Clin. Oncol., Apr;28(12):2108-13 (2010)
The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy.
Cancer., Mar;117(5):948-56 (2011)
Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer.
Clin. Cancer Res., Mar;18(5):1464-71 (2012)
Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake.
Cancer., Aug;115(15):3548-54 (2009)
Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer.
Int. J. Radiat. Oncol. Biol. Phys., Jul;77(4):1085-91 (2010)
Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors.
Gynecol. Oncol., Mar;116(3):438-41 (2010)
Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage cervical cancer.
Gynecol. Oncol., Mar;116(3):539-43 (2010)
Long-term assessment of bladder and bowel dysfunction after radical hysterectomy.
Gynecol. Oncol., Jul;114(1):75-9 (2009)
ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes.
J. Clin. Oncol., Jul;27(19):3091-6 (2009)
Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer.
Gynecol. Oncol., Jan;112(1):104-9 (2009)
Phase I study and preliminary pharmacology of the novel innate immune modulator rBBX-01 in gynecologic cancers.
Clin. Cancer Res., May;14(10):3089-97 (2008)
Differential display identifies overexpression of the USP36 gene, encoding a deubiquitinating enzyme, in ovarian cancer.
Int J Med Sci., 5(3):133-42 (2008)
Acute toxicity of postoperative IMRT and chemotherapy for endometrial cancer.
Radiat Med., Nov;25(9):439-45 (2007)
CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer.
Cancer Res., Dec;67(23):11202-8 (2007)
Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type.
J. Clin. Oncol., May;25(15):2042-8 (2007)
External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer.
Gynecol. Oncol., Jul;106(1):215-20 (2007)
Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma.
Int. J. Radiat. Oncol. Biol. Phys., Feb;67(2):480-4 (2007)
DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis.
Mod. Pathol., Oct;19(10):1333-8 (2006)
Colposcopic accuracy of obstetrics and gynecology residents.
Gynecol. Oncol., Dec;103(3):966-70 (2006)
MLH3 mutation in endometrial cancer.
Cancer Res., Aug;66(15):7502-8 (2006)
Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
Gynecol. Oncol., Nov;103(2):637-41 (2006)
Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer.
Gynecol. Oncol., Nov;103(2):489-93 (2006)
CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
Gynecol. Oncol., Oct;103(1):212-8 (2006)
Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer.
Oncogene., Aug;25(39):5436-45 (2006)
Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history.
Am. J. Hum. Genet., Jun;74(6):1262-9 (2004)
Panniculectomy: improving lymph node yield in morbidly obese patients with endometrial neoplasms.
Gynecol. Oncol., Aug;94(2):436-41 (2004)
Expression and localization of GRP75 in human epithelial tumors and normal tissues.
Appl. Immunohistochem. Mol. Morphol., Jun;12(2):132-8 (2004)
Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.
Clin. Cancer Res., Nov;10(21):7220-8 (2004)
Cervical carcinoma in the elderly: an analysis of patterns of care and outcome.
Cancer., Jan;103(1):85-91 (2005)
Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma.
Gynecol. Oncol., Jul;98(1):84-91 (2005)
Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer.
Gynecol. Oncol., Dec;95(3):546-51 (2004)
IGSF4 promoter methylation and expression silencing in human cervical cancer.
Gynecol. Oncol., Jan;96(1):150-8 (2005)
Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence.
Int. J. Radiat. Oncol. Biol. Phys., Feb;61(2):450-5 (2005)
Fine mapping and evaluation of candidate genes for cervical cancer on 11q23.
Genes Chromosomes Cancer., May;43(1):95-103 (2005)
FDG-PET evaluation of vaginal carcinoma.
Int. J. Radiat. Oncol. Biol. Phys., Jul;62(3):733-7 (2005)
Cervical dysplasia in adolescents.
Obstet Gynecol., Jul;106(1):115-20 (2005)
Cervical sarcomas: an analysis of incidence and outcome.
Gynecol. Oncol., Nov;99(2):348-51 (2005)
Resource utilization for ovarian cancer patients at the end of life: how much is too much?
Gynecol. Oncol., Nov;99(2):261-6 (2005)
Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography.
Cancer., Dec;104(11):2484-91 (2005)
Relationship of ovarian neoplasms and body mass index.
J Reprod Med., Aug;50(8):595-602 (2005)
Long-term outcome of women who undergo panniculectomy at the time of gynecologic surgery.
Gynecol. Oncol., Jul;102(1):86-91 (2006)
Human papillomavirus triage for young women with atypical squamous cells of undetermined significance.
Obstet Gynecol., Apr;107(4):822-9 (2006)
Identification of chromosomal alterations important in the development of cervical intraepithelial neoplasia and invasive carcinoma using alignment of DNA microarray data.
Gynecol. Oncol., Nov;103(2):458-62 (2006)
Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.
Cancer., Jul;107(1):83-9 (2006)
Denaturing high-performance liquid chromatography for detecting and typing genital human papillomavirus.
J. Clin. Microbiol., Dec;41(12):5563-71 (2003)
Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation.
Clin. Cancer Res., Jan;10(2):481-90 (2004)
Synchronous ovarian metastases at the time of laparotomy for colon cancer.
Gynecol. Oncol., Mar;92(3):851-5 (2004)
Double cervix with bilateral and synchronous HSIL associated with different high-risk HPV types. A case report.
Acta Cytol., 48(2):273-7 (2004)
Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignancies.
Gynecol. Oncol., Oct;91(1):134-8 (2003)
Acute abdominal pain with a calcified pelvic mass.
J Pediatr Adolesc Gynecol., Aug;16(4):237-41 (2003)
A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer.
Gynecol. Oncol., Nov;91(2):318-25 (2003)
Factors predicting subcutaneous implanted central venous port function: the relationship between catheter tip location and port failure in patients with gynecologic malignancies.
Gynecol. Oncol., Dec;83(3):533-6 (2001)
Role of the ultrasonic surgical aspirator in gynecology.
Obstet. Gynecol. Clin. North Am., Dec;28(4):775-90 (2001)
Use of complementary and alternative medicine among women with gynecologic cancers.
Gynecol. Oncol., Mar;84(3):363-7 (2002)
Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia.
Gynecol. Oncol., Jul;86(1):62-8 (2002)
The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies.
Gynecol. Oncol., Jul;86(1):79-84 (2002)
Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker.
Cancer., Jun;94(11):2941-52 (2002)
Phase I study of rubitecan and gemcitabine in patients with advanced malignancies.
Ann. Oncol., Nov;13(11):1819-25 (2002)
Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers.
Proc. Natl. Acad. Sci. U.S.A., May;100(10):5908-13 (2003)
Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma.
Clin. Cancer Res., Jun;9(6):2277-87 (2003)
Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies.
Cancer., Aug;98(3):610-7 (2003)
A relationship between methylenetetrahydrofolate reductase variants and the development of invasive cervical cancer.
Gynecol. Oncol., Sep;90(3):560-5 (2003)
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.
Cancer Chemother. Pharmacol., Jun;67(6):1225-37 (2011)
Cardiac arrest during laparotomy with argon beam coagulation of metastatic ovarian cancer.
Int. J. Gynecol. Cancer., Feb;19(2):237-8 (2009)
A unified sample preparation protocol for proteomic and genomic profiling of cervical swabs to identify biomarkers for cervical cancer screening.
Proteomics Clin Appl., Dec;2(12):1658-69 (2008)
Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer.
Gynecol. Oncol., Mar;104(3):535-9 (2007)
Outcomes in 24 selected patients with stage IVB cervical cancer and excellent performance status treated with radiotherapy and chemotherapy.
Radiat Med., Nov;24(9):625-30 (2006)